AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
(From India Business Insight)
Glenmark Pharmaceuticals and the $2-billion USA-based Forest Laboratories have entered into a collaboration agreement to develop the PDE4 inhibitor GRC 3886, which is a compound developed by Glenmark. The drug is in development for chronic obstructive pulmonary disorder (COPD) and asthma.
As per the accord, Forest will develop, …